GlassScriptPhysician profile
Scott P Serden
NPI 1013928837
$4,272.32
in general payments reported to CMS, 2019-2025
30 companies · $995 in 2025
The $995 reported for 2025 was more than what 90% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $554 · 2020: $118 · 2021: $430 · 2022: $680 · 2023: $1,093 · 2024: $402 · 2025: $995.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,490.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,490.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,042.58 | 2019-2025 | Ubrelvy, Lo Loestrin Fe, Liletta |
| Mayne Pharma Commercial LLC | $399.22 | 2021-2025 | |
| Pfizer INC. | $385.22 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $304.49 | 2019-2025 | |
| Therapeuticsmd, INC. | $297.44 | 2019-2022 | |
| Exeltis, USA INC. | $240.26 | 2019-2025 | Slynd |
| Sumitomo Pharma America, INC. | $183.81 | 2023-2025 | Myfembree, Gemtesa |
| Evofem Biosciences, INC. | $162.46 | 2021-2025 | Phexxi, Solosec, Phexx |
| Agile Therapeutics, INC. | $154.79 | 2022-2024 | Twirla |
| Ascend Therapeutics US, LLC | $123.67 | 2020-2023 | |
| Sage Therapeutics, LLC | $119.02 | 2025 | Zurzuvae |
| Coopersurgical, INC. | $118.44 | 2020-2025 | Paragard T 380a, Paragard T 380a |
| Novo Nordisk INC | $108.71 | 2022-2025 | Wegovy |
| Astellas Pharma US INC | $99.97 | 2023-2025 | Veozah |
| Millicent US INC | $64.67 | 2025 | Femlyv, Intrarosa |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $50.27 | 2022-2023 | Quviviq |
| Baxter Healthcare | $48.50 | 2022 | |
| Daiichi Sankyo INC. | $45.79 | 2019-2020 | |
| Allergan, INC. | $44.27 | 2019 | |
| Amag Pharmaceuticals, INC. | $40.05 | 2019-2020 | |
| Aspira Women'S Health INC | $37.92 | 2023 | Ova1 |
| Alnylam Pharmaceuticals INC. | $28.55 | 2023 | Givlaari |
| Vertical Pharmaceuticals, LLC | $26.83 | 2019-2020 | |
| Channel Medsystems, INC. | $25.19 | 2022 | |
| Myovant Sciences INC. | $24.78 | 2022 | |
| Hologic Sales and Service, LLC | $23.43 | 2024 | Aptima |
| Avion Pharmaceuticals | $21.46 | 2022 | |
| Scynexis, INC. | $19.03 | 2022 | |
| Supernus Pharmaceuticals, INC. | $18.21 | 2025 | Qelbree |
| Mycovia Pharmaceuticals, INC. | $13.29 | 2023 | Vivjoa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Serden listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.